Early-stage clinical trial results published by researchers at the Johns Hopkins School of Medicine suggest a novel vaccine may help prevent pancreatic cancer in individuals with a high genetic risk for the disease. In a phase 1 study, the mKRAS-VAX vaccine demonstrated a strong safety profile and triggered persistent immune responses in participants, with no subjects developing cancer during the follow-up period.
Targeting Genetic Mutations to Prevent Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common and aggressive form of pancreatic cancer, with a five-year survival rate of 13 percent, according to Neeha Zaidi, MD. Because the disease often remains asymptomatic until it reaches advanced stages, early detection and prevention strategies are a major focus of current oncology research.
The mKRAS-VAX vaccine is specifically designed to target mutations in the KRAS gene, which are present in more than 90 percent of pancreatic ductal adenocarcinomas. By stimulating the immune system to recognize and neutralize cells harboring these specific mutations, the vaccine aims to intercept the disease at the precancerous stage. According to Neeha Zaidi, MD, an associate professor of oncology at the Johns Hopkins School of Medicine, the vaccine works by activating T cells—a type of white blood cell—to detect and respond to cancerous or precancerous lesions.
Phase 1 Clinical Trial Outcomes
In the initial safety trial, researchers administered the vaccine to 20 high-risk adults who had documented pancreatic lesions or cysts. The study protocol involved a primary series of three injections at weeks 1, 3, and 5, followed by a booster dose at week 13.
The results, which tracked participants for an average of 16.5 months, showed:
- Immune Response: 90 percent of participants exhibited a T-cell response, which remained detectable in blood samples two years after the initial vaccination.
- Clinical Safety: No participants developed pancreatic cancer during the study period. Patients reported only mild side effects, such as injection site reactions and flu-like symptoms.
- Lesion Regression: Vaccinated individuals saw a 38 percent reduction in the size of their pancreatic cysts, compared to a 6.8 percent reduction observed in a control group.
Expert Perspectives on Preventive Oncology
While these findings are promising, experts emphasize that they are preliminary. Peter Hosein, MD, an associate director for clinical research at Sylvester Comprehensive Cancer Center, noted that while the trial provides a potential "holy grail" approach by intercepting cancer before it progresses, larger studies are required to confirm these benefits.
Jaekyung Cheon, MD, an oncologist at Moffitt Cancer Center, highlighted that the study represents a shift in research focus. Most pancreatic cancer research has historically prioritized treating advanced-stage disease, whereas this trial evaluates a proactive, preventive approach for individuals identified as high-risk due to genetic predisposition or the presence of precancerous cysts.
Next Steps in Vaccine Research
The research team is currently enrolling a new cohort of high-risk patients to receive the vaccine prior to undergoing surgical removal of precancerous lesions. This follow-up study aims to determine if the T cells generated by the vaccine effectively infiltrate and target risky tissues. Future trials will also need to utilize larger sample sizes and more rigorous clinical endpoints to further validate the vaccine’s long-term efficacy in preventing pancreatic cancer.
Worth a look